Investor Centre
Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
0.52 GBX
Volume:
968,485
Market Capitalisation (m)
£2.22
TheraCryf plc Full Year Results
Voting on AGM Resolutions
18 - July - 2024Results of voting on resolutions following TheraCryf's AGM held on Thursday 18th July 2024.
TheraCryf plc - Research and Development Update
14 - June - 2024TheraCryf plc present an update on the Company including current status of R&D projects.
| Company | Analyst |
|---|---|
| Cavendish | Chris Donnellan |
| Capital Access Group | Colin Smith |
Major Shareholder
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| J. R. Kight | 34,600,000 | 8.10% |
| First Equity Limited | 31,200,000 | 7.30% |
| Rathbones Investment Management Ltd | 25,789,246 | 6.03% |
| Octopus Investments | 21,875,000 | 5.12% |
| Vulpes Investment Management Pte Ltd | 20,554,191 | 4.81% |
| Seneca Partners Limited | 16,301,456 | 3.81% |
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.
